Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Michael B Jameson & Michelle Head. (2011) Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA). Expert Opinion on Drug Metabolism & Toxicology 7:10, pages 1315-1326.
Read now
Read now
Shufeng Zhou, Philip Kestell & James W. Paxton. (2002) PREDICTING PHARMACOKINETICS AND DRUG INTERACTIONS IN PATIENTS FROM IN VITRO AND IN VIVO MODELS: THE EXPERIENCE WITH 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID (DMXAA), AN ANTI-CANCER DRUG ELIMINATED MAINLY BY CONJUGATION. Drug Metabolism Reviews 34:4, pages 751-790.
Read now
Read now
Articles from other publishers (17)
Daigo Asano, Koichi Nakamura, Yumi Nishiya, Hideyuki Shiozawa, Hideo Takakusa, Takahiro Shibayama, Shin-ichi Inoue, Tsuyoshi Shinozuka, Takakazu Hamada, Chizuko Yahara, Nobuaki Watanabe & Kouichi Yoshinari. (2023)
Physiologically Based Pharmacokinetic Modeling for Quantitative Prediction of Exposure to a Human Disproportionate Metabolite of the Selective Na
V
1.7 Inhibitor DS-1971a, a Mixed Substrate of Cytochrome P450 and Aldehyde Oxidase, Using Chimeric Mice With Humanized Liver
. Drug Metabolism and Disposition 51:1, pages 67-80.
Crossref
Crossref
Raymond Yung, Vahid Seyfoddin, Christopher Guise, Sofian Tijono, Ailsa McGregor, Bronwen Connor & Lai-Ming Ching. (2014) Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma. Cancer Chemotherapy and Pharmacology 73:3, pages 639-649.
Crossref
Crossref
Yasmine S. Touil, Nicolas Auzeil, François Boulinguez, Hanane Saighi, Anne Regazzetti, Daniel Scherman & Guy G. Chabot. (2011) Fisetin disposition and metabolism in mice: Identification of geraldol as an active metabolite. Biochemical Pharmacology 82:11, pages 1731-1739.
Crossref
Crossref
Keigo Kosaka, Norifumi Sakai, Yuya Endo, Yuga Fukuhara, Minoru Tsuda-Tsukimoto, Tatsuyuki Ohtsuka, Ichiro Kino, Tomohiko Tanimoto, Naomi Takeba, Masakatsu Takahashi & Toshiyuki Kume. (2011) Impact of Intestinal Glucuronidation on the Pharmacokinetics of Raloxifene. Drug Metabolism and Disposition 39:9, pages 1495-1502.
Crossref
Crossref
Shufeng Zhou, Philip Kestell & James W Paxton. (2002) Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species. Journal of Pharmacy and Pharmacology 54:7, pages 997-1003.
Crossref
Crossref
Yuji Mano, Takashi Usui & Hidetaka Kamimura. (2008) Species Differences in Inhibition Potential of Nonsteroidal Anti-Inflammatory Drugs Against Estradiol 3β-Glucuronidation Between Rats, Dogs, and Humans. Journal of Pharmaceutical Sciences 97:7, pages 2805-2810.
Crossref
Crossref
Carlos Arturo Navas, José Guilherme Chaui-Berlinck, José Eduardo P.W. Bicudo, Vânia R. Pivello & Marcio Martins. (2007) Comparative biochemistry and physiology in Brazil: A critical appraisal. Comparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology 147:3, pages 586-593.
Crossref
Crossref
María José Gómez-Lechón, José Vicente Castell & María Teresa Donato. (2007) Hepatocytes—the choice to investigate drug metabolism and toxicity in man: In vitro variability as a reflection of in vivo. Chemico-Biological Interactions 168:1, pages 30-50.
Crossref
Crossref
Johnson J. Liu, Lai-Ming Ching, Michael Goldthorpe, Rachel Sutherland, Bruce C. Baguley, James A. Kirker & Mark J. McKeage. (2006) Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours. Cancer Chemotherapy and Pharmacology 59:5, pages 661-669.
Crossref
Crossref
Lesley D. McPhail, Dominick J.O. McIntyre, Christian Ludwig, Philip Kestell, John R. Griffiths, Lloyd R. Kelland & Simon P. Robinson. (2006) Rat Tumor Response to the Vascular-Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Plasma 5-Hydroxyindoleacetic Acid Levels, and Tumor Necrosis. Neoplasia 8:3, pages 199-206.
Crossref
Crossref
Shufeng Zhou, Xia Feng, Philip Kestell, James W. Paxton, Bruce C. Baguley & Eli Chan. (2005) Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. European Journal of Pharmaceutical Sciences 24:5, pages 513-524.
Crossref
Crossref
Shufeng Zhou, Yan Li, Phillip Kestell, Peter Schafer, Eli Chan & James W. Paxton. (2005) Transport of thalidomide by the human intestinal Caco-2 monolayers. European Journal of Drug Metabolism and Pharmacokinetics 30:1-2, pages 49-61.
Crossref
Crossref
Horst Messinger, Marcus Kleber & Walter Aulmann. (2004) Nephrotoxicity of 4-cycloocten-1-carbaldehyde. Archives of Toxicology 78:12, pages 716-722.
Crossref
Crossref
Shufeng Zhou, Xia Feng, Philip Kestell, Bruce C. Baguley & James W. Paxton. (2004) Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. Journal of Chromatography B 809:1, pages 87-97.
Crossref
Crossref
Shufeng Zhou, Philip Kestell, Bruce C. Baguley & James W. Paxton. (2003) Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochemical Pharmacology 65:11, pages 1853-1865.
Crossref
Crossref
Shufeng Zhou, Philip Kestell & James W Paxton. (2002) Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice. Journal of Chromatography B 776:2, pages 231-236.
Crossref
Crossref
Shufeng Zhou, Philip Kestell, Bruce C. Baguley & James W. Paxton. (2002) 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA): a New Biological Response Modifier for Cancer Therapy. Investigational New Drugs 20:3, pages 281-295.
Crossref
Crossref